Dark

AKTX
Akari Therapeutics plc ADR (0.01 USD)
stock NASDAQ ADR

Market Open

Jun 27, 2025 3:59:30 PM EDT

1.16USD0.000%(0.00)722

0.00Bid 0.00Ask 0.00Spread

Pre-market

Jun 26, 2025 9:17:30 AM EDT

1.14USD-1.648%(-0.02)0

After-hours

0.00USD0.000%(0.00)0

OverviewHistoricalExchangesShortsNews

Jan 26, 2022

08:30AM EST Akari Advances Lung Program with Inhaled Nomacopan Focused on GlobeNewswire Inc

Jan 19, 2022

08:36AM EST Akari Therapeutics Reports FDA Has Agreed To The Clinical Use Of Co.'s Nomacopan Derived From Next-Gen Manufacturing Process Benzinga

08:30AM EST FDA Agrees to Use of New Higher-Yielding Manufacturing Process for GlobeNewswire Inc

Jan 4, 2022

07:00AM EST Akari Therapeutics to Present at H.C. Wainwright BioConnect GlobeNewswire Inc

Dec 30, 2021

11:11AM EST Akari Therapeutics Announces $6M Registered Direct Offering Benzinga

11:04AM EST Akari Therapeutics, Plc Announces $6.0 Million Registered Direct GlobeNewswire Inc

Dec 3, 2021

07:48AM EST Akari Therapeutics Q3 EPS $0.00, Same YoY Benzinga

07:45AM EST Akari Therapeutics Reports Third Quarter 2021 Financial Results GlobeNewswire Inc

Dec 1, 2021

08:35AM EST Akari Therapeutics Highlights Presentation Of New Data Revealing Potential Mechanism Of Action Driving Serious Exacerbations Across Lung Disorders Benzinga

08:30AM EST Akari Therapeutics Presents New Data Revealing Potential Mechanism GlobeNewswire Inc

Oct 26, 2021

08:00AM EDT Akari Therapeutics Announces Presentation at Annual GlobeNewswire Inc

Oct 25, 2021

08:30AM EDT -- Nomacopan eyedrops reduced inflammation more than both standard treatments cyclosporin and the steroid dexamethasone in a model of allergic eye disease -- Building on early clinical data in atopic keratoconjunctivitis (AKC), Akari is now advancing its surface of the eye program GlobeNewswire Inc

Sep 22, 2021

09:01AM EDT Akari Therapeutics To Present At Cantor Virtual Global Healthcare Conference On Thursday, Sept. 30 At 1:20 p.m. EDT Benzinga

09:00AM EDT Akari Therapeutics to Present at the Cantor Virtual Global GlobeNewswire Inc

08:34AM EDT Akari Therapeutics Q2 EPS $0.00, Unchanged On Year-Over-Year Basis Benzinga

08:30AM EDT Akari Therapeutics Reports Second Quarter 2021 Financial Results GlobeNewswire Inc

Sep 10, 2021

08:34AM EDT Akari Therapeutics To Present Phase 3 Plans For Nomacopan In Patients With Bullous Pemphigoid At 2021 International Pemphigus & Pemphigoid Foundation (IPPF) Scientific Symposium Benzinga

08:30AM EDT Akari Therapeutics to Present Its Phase III Plans for Nomacopan in GlobeNewswire Inc

Sep 7, 2021

07:00AM EDT Akari Therapeutics to Present at the H.C. Wainwright Global GlobeNewswire Inc

Jul 7, 2021

09:16AM EDT Akari Therapeutics Announces Private Placement At Purchasing Price Of $1.55/ADS Benzinga

09:15AM EDT Akari Therapeutics Announces Private Placement GlobeNewswire Inc

Jun 29, 2021

04:04PM EDT Akari Therapeutics Reports Q1 Net Loss $5.8M Compared To $3.7M YoY Benzinga

04:01PM EDT -- Open Investigational New Drug Application (IND) with U.S. Food and Drug Administration (FDA) for Phase III study of nomacopan in bullous pemphigoid (BP) GlobeNewswire Inc

Apr 28, 2021

10:25AM EDT Akari Therapeutics' Nomacopan Secures Expediated Review Tag For Blistering Skin Disorder Benzinga

08:26AM EDT Akari Therapeutics Receives FDA Fast Track Designation for Nomacopan for the Treatment of Bullous Pemphigoid Benzinga

08:00AM EDT Akari Therapeutics Receives FDA Fast Track Designation for GlobeNewswire Inc

Apr 22, 2021

07:32AM EDT Akari Therapeutics Announces Poster Presentation Of Phase II Bullous Pemphigoid Disease And Phase III Trial Design At American Academy Of Dermatology Association Virtual Meeting Experience Apr. 23 Benzinga

07:30AM EDT Akari Therapeutics, Plc (Nasdaq: AKTX), a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where the complement and leukotriene systems are implicated, announced today that it will present a poster at the American Academy of Dermatology Association (AAD) Virtual Meeting Experience (VMX) taking place April 23-25, 2021. GlobeNewswire Inc

Apr 20, 2021

06:41PM EDT -- Opening of Investigational New Drug Application (IND) with U.S. Food and Drug Administration (FDA) for Phase III study of nomacopan in bullous pemphigoid (BP), a severe dermatological disease with no specific approved treatments GlobeNewswire Inc

Apr 12, 2021

12:48PM EDT Akari Therapeutics' To Go With Pivotal Bullous Pemphigoid Study With Nomacopan Benzinga

11:00AM EDT Akari Therapeutics Initiates Pivotal Phase III Trial Of Nomacopan In Bullous Pemphigo RTTNews

10:34AM EDT Akari Therapeutics shares were trading higher after the company announced an IND is now open with the FDA for its multicenter Phase III study with nomacopan for the treatment of moderate and severe BP, allowing clinical sites to open mid-2021. Benzinga

10:17AM EDT Akari Therapeutics Announces Initiation Of Pivotal Phase III Trial Of Nomacopan In Bullous Pemphigoid Benzinga

10:16AM EDT Akari Therapeutics Announces Initiation of Pivotal Phase III Trial GlobeNewswire Inc

Mar 4, 2021

08:33AM EST Akari Therapeutics Reports Cooperative R&D Deal With US Army Institute Of Surgical Research For Nomacopan In Trauma, No Terms Disclosed Benzinga

08:30AM EST Akari Therapeutics Announces a Cooperative Research and GlobeNewswire Inc

Feb 25, 2021

01:41PM EST Akari Therapeutics' PASylated Nomacopan Shows Promising Action In Animal Studies Benzinga

09:24AM EST Akari Therapeutics Highlights Presentation Of Preclinical Data For Long-Acting PASylated Nomacopan To Treat Retinal Diseases Benzinga

09:07AM EST Akari Therapeutics Presents New Preclinical Data Highlighting GlobeNewswire Inc

Feb 23, 2021

07:25AM EST The Daily Biotech Pulse: Aridis To Study Antibody Cocktail For Coronavirus Variants, Revance & Protalix Data Readouts Benzinga

Feb 1, 2021

09:32AM EST Akari Therapeutics Reports Added Histamine Inhibitor Votucalis To Pipeline To Treat Neuropathic Pain, Dermatological Disease Benzinga

09:30AM EST Akari Therapeutics Adds Histamine Inhibitor Votucalis to Pipeline GlobeNewswire Inc

Jan 21, 2021

08:05AM EST The Daily Biotech Pulse: Addex Jumps On Positive Data For Out-Licensed Drug, COVID-19 Vaccine Developer Inovio Announces $150M Follow-On Offering, Boston Scientific Goes Shopping Benzinga

Jan 20, 2021

07:32AM EST The Daily Biotech Pulse: FDA Greenlights Merck's Heart Failure Drug, Histogen Hit With Clinical Hold, Aptorum Gets Nod For Commencing Human Study Benzinga

Jan 6, 2021

09:32AM EST Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where complement (C5) and/or leukotriene (LTB4) systems are implicated, today announced that Clive Richardson, Chief Executive Officer, will participate in the following two upcoming virtual investor conferences. GlobeNewswire Inc

Dec 11, 2020

09:03AM EST Akari Therapeutics Q3 EPS $0.00 Benzinga

09:00AM EST Akari Therapeutics Reports Third Quarter 2020 Financial Results GlobeNewswire Inc

08:58AM EST Akari Therapeutics Announces 'Transfusion independence of 79% reported for 14 formerly transfusion dependent PNH patients treated with nomacopan for at least six months' Benzinga

08:56AM EST Akari Therapeutics Announces New Clinical Data Showing Self-Administered Nomacopan Is 'Well-Tolerated and Substantially Reduces Transfusion Dependence in Patients with Paroxysmal Nocturnal Hemoglobinuria' Benzinga

08:55AM EST Akari Therapeutics Announces New Clinical Data that Show Long-Term GlobeNewswire Inc

Dec 3, 2020

10:01AM EST Akari Therapeutics Announces Publication In American Journal Of Pathology Highlighting Potential Of Nomacopan In Treatment Of Uveitis And Retinal Disease Benzinga

10:00AM EST Akari Therapeutics Announces Publication in American Journal of GlobeNewswire Inc

Oct 29, 2020

07:30AM EDT The Daily Biotech Pulse: Novartis Acquires Gene Therapy Company, Moderna's Japanese Vaccine Supply Deal Benzinga

Oct 27, 2020

09:03AM EDT Akari Therapeutics To Present Phase II Data From Bullous Pemphigoid Trial At European Academy Of Dermatology And Venereology (EADV) Virtual Congress October 29 Benzinga

09:00AM EDT -- Safety and efficacy data from Phase II clinical trial of nomacopan in adults with mild to moderate BP -- The Phase II data was the basis for the agreement of the FDA and the EMA that Akari may proceed to a Phase III randomised placebo-controlled study using nomacopan for treatment of BP GlobeNewswire Inc

Oct 6, 2020

08:39AM EDT Akari Announces Further Progress In COVID-19 Pneumonia Program With Nomacopan In US, Brazil RTTNews

08:35AM EDT Akari Therapeutics Announces Further Clinical Trial Progress Using Nomacopan To Treat COVID-19 Pneumonia Benzinga

08:30AM EDT Akari Therapeutics Announces Further Clinical Trial Progress Using GlobeNewswire Inc

Oct 1, 2020

09:38AM EDT Akari Therapeutics Reports Successful Scientific Advice Meeting with EMA For Nomacopan For Treatment Of Bullous Pemphigoid Benzinga

09:00AM EDT Akari Therapeutics Announces Successful Scientific Advice Meeting GlobeNewswire Inc

Sep 29, 2020

11:10AM EDT Akari Therapeutics To Present Its Phase III Plans At IPPF Patient Education Conference RTTNews

09:30AM EDT Akari Therapeutics to Present Its Phase III Plans at the GlobeNewswire Inc

Sep 10, 2020

10:19AM EDT Akari Therapeutics to Participate in Two September Virtual GlobeNewswire Inc

Sep 1, 2020

08:50AM EDT Akari Therapeutics Q2 2020 EPS $0.00; Total Assets $14.45M Benzinga

08:39AM EDT Akari Therapeutics Q2 Net Loss $8.3 Mln Vs Net Loss $4.1 Mln Last Year RTTNews

08:30AM EDT Akari Therapeutics Reports Second Quarter 2020 Financial Results GlobeNewswire Inc

Aug 31, 2020

07:09AM EDT Akari Therapeutics Announces Intl Clinical Development Program Of Nomacopan For COVID-19 Pneumonia RTTNews

07:03AM EDT Akari Therapeutics Announces International Clinical Development Program Of Nomacopan For Potential Treatment Of COVID-19 Pneumonia Benzinga

07:00AM EDT Akari Therapeutics Announces International Clinical Development GlobeNewswire Inc

Aug 12, 2020

08:27AM EDT Akari Therapeutics Says 'The FDA has agreed to a two-part pivotal trial with Part A and Part B having the same structure, duration, endpoints and target population of moderate and severe BP patients.' Benzinga

08:27AM EDT Akari Therapeutics Announces End Of Meeting With FDA To Initiate Pivotal Phase III Study For Treatment Of Bullous Pemphigoid With Nomacopan Benzinga

08:24AM EDT Akari Therapeutics Announces Successful End-of-Phase II Meeting GlobeNewswire Inc